FDA expected to lift peptide compounding ban at RFK Jr.'s urging; 30 telehealth firms warned; Novo slashes Ozempic prices in India; UK expands Wegovy prescribing.
10 stories · Covering regulatory, industry, clinical-trials, research
Today's peptide news is dominated by a seismic regulatory shift: the FDA is expected to lift its 2023 ban on 14 compounding peptides — including BPC-157, CJC-1295, and Ipamorelin — at the urging of Health Secretary RFK Jr. The story broke via the New York Times and was picked up by NPR, Reuters, Ars Technica, Gizmodo, and others, sparking fierce debate between wellness advocates and safety-minded experts. Meanwhile, the FDA simultaneously cracked down on 30 telehealth companies for illegally marketing compounded GLP-1 drugs. On the business side, Novo Nordisk slashed Ozempic and Wegovy prices up to 48% in India to fight off generics, and the UK expanded Wegovy prescribing to cardiovascular prevention. Orforglipron remains on track for an April FDA decision that could reshape the oral GLP-1 market.
The FDA is moving to allow compounding pharmacies to produce 14+ injectable peptides banned in 2023. Health Secretary RFK Jr. publicly backed the reversal, while top FDA leaders reportedly have reservations about politically-driven decisions.
The FDA issued warning letters to 30 telehealth firms for false or misleading claims about compounded GLP-1 weight-loss products, signaling a major crackdown on illegal online marketing.
Novo Nordisk cut Ozempic prices 36% and Wegovy 48% in India as generic semaglutide from Dr Reddy's, Sun Pharma, and Zydus entered the market with prices as low as Rs 1,290/month.
Under new UK guidance, GPs can prescribe semaglutide (Wegovy) to overweight patients who have had heart attacks, strokes, or serious circulation problems, expanding its use beyond weight management.
Eli Lilly's oral GLP-1 drug orforglipron is among the most consequential FDA decisions in Q2 2026. Analysts expect it to help Lilly's tirzepatide franchise exceed $100 billion in peak revenue.
Longevity enthusiasts anticipate FDA loosening restrictions on BPC-157, ipamorelin, and MOTs-C. Industry notes it may take months for compounding pharmacies to ramp up supply after reclassification.
Eric Topol of Scripps Research called peptide data "woefully minuscule," warning about impurities, random dosing, and dangerous stacking of unproven compounds from gray-market sources.
Oral peptide icotrokinra delivered complete skin clearance through week 52 with a strong safety profile in the ICONIC-ADVANCE trials, presented at the American Academy of Dermatology meeting.
Patients switching from dulaglutide to tirzepatide reported greater improvement in weight-related self-perception at week 40, highlighting benefits beyond glycemic control.
Analysts expect Novo's aggressive cuts to capture the lion's share of India's GLP-1 market in 12-18 months. Eli Lilly's Mounjaro currently dominates with ~79% share vs Novo's ~21%.